Arrowpoint Investment Partners’s United Therapeutics UTHR Stock Holding History

Arrowpoint Investment Partners’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,500	Closed	-$1.07M	–	145
2025 Q3	$1.07M	Buy	+2,500	New	+$841K	1.07%	26

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Arrowpoint Investment Partners's UTHR Position: Q1 2026 in Review

Arrowpoint Investment Partners opened a new position in United Therapeutics (UTHR) in Q1 2026: 527 shares worth $313K. The stake represents 0.28% of the portfolio and ranks #55 among its holdings.

851 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

Arrowpoint Investment Partners held 527 shares of United Therapeutics worth $313K as of Q1 2026.
United Therapeutics was a new Arrowpoint Investment Partners position in Q1 2026.
United Therapeutics made up 0.28% of Arrowpoint Investment Partners's portfolio in Q1 2026, its #55 holding.
851 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q1 2026, filed 14 May 2026.